ProBioGen Appoints Dr. Alfred Merz as CEO

• ProBioGen has appointed Dr. Alfred Merz as its Chief Executive Officer, effective 1 April 2025.

• Dr. Merz, previously COO and interim CEO, brings over 30 years of industry experience from companies including Bayer and Novartis.

ProBioGen has announced the appointment of Dr. Alfred Merz, PhD, as its new Chief Executive Officer, effective 1 April 2025. Dr. Merz previously served as the company’s Chief Operating Officer and interim CEO.

Dr. Merz joined ProBioGen in 2024 from Bayer Pharmaceuticals, where he held the role of Senior Vice President and Head of Product Supply Medical Devices. With more than three decades of experience in manufacturing, operational excellence, and strategy development, he has worked with major pharmaceutical and biotech companies, including Bayer and Novartis. His leadership will support ProBioGen’s continued expansion in biopharmaceutical development and contract manufacturing.

“ProBioGen has a strong legacy of innovation and excellence in CDMO services and technologies,” said Dr. Alfred Merz. “I am honored to lead this outstanding team as we accelerate our growth, expand our capabilities, and continue delivering high-quality solutions for our pharma and biotech partners.”

Dr. Wafik Bardissi, Chairman of ProBioGen’s Supervisory Board and CEO of Minapharm Pharmaceuticals SAE, expressed confidence in Dr. Merz’s leadership, citing his strategic expertise as essential to driving the company’s next growth phase and advancing its proprietary technologies.